Company intelligence / Profile preview

Maroon

Evanston, Illinois, United States

Ownership: Private
Development stage: Other

Overview

Maroon Therapeutics is a clinical-stage biotechnology company focused on developing first-in-class therapies for inflammatory and fibrotic diseases. The company's lead asset, MTX-101, is a topical small molecule p38 MAPK inhibitor currently being evaluated in Phase 2 clinical trials for the treatment of calciphylaxis and hidradenitis suppurativa. Maroon Therapeutics leverages its expertise in inflammatory signaling pathways to address high-unmet-need conditions in dermatology and beyond. The company is headquartered in Evanston, Illinois, and has received significant support through federal research grants.

Therapeutic areas: DermatologyNephrology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Maroon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Maroon.

Explore the full profile